ArticleNature2023
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06518382 (A Retrospective Observational Study Characterizing Tumour-microenvironment Spatial Interaction Aimed at the Identification of New Markers of Resistance to Therapy in HER2-positive Breast Cancer Patients), which is not on this map. Cited by 234 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
234citing papers in PubMed, 1 pooled it
65.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Retrospective Observational Study Characterizing Tumour-microenvironment Spatial Interaction Aimed at the Identification of New Markers of Resistance to Therapy in HER2-positive Breast Cancer Patients
Who cites it
234 citing papers in PubMed, 1 synthesis or guideline pooled it, 286 citations in OpenAlex.
- PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies.Molecular cancer · 2024Pooled it
- Tumor flare-like response: A novel imaging phenomenon with predictive significance in triple negative breast cancer patients undergoing neoadjuvant immuno-chemotherapy.Breast (Edinburgh, Scotland) · 2026Trial
- Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.Cell reports. Medicine · 2026Trial
- Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.Nature communications · 2026Trial
- Trial
- Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.Nature cancer · 2026Trial
- Biologically-informed integration of drug representations for breast cancer treatment using deep learning.Nature communications · 2025Trial
- Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial.Nature aging · 2025Trial
- Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial.Signal transduction and targeted therapy · 2024Trial
- The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- OpenDVP: an experimental and computational framework for community-empowered deep visual proteomics.Nature methods · 2026Article
- Multi-Omics Integration Reveals Metabolic Reprogramming and EMT-Driven Metastasis in Triple-Negative Breast Cancer.Cancer science · 2026Article
- Unveiling the role of spatial transcriptomics in the analysis of the tumor immune microenvironment (Review).International journal of molecular medicine · 2026Review
- Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemoimmunotherapy in triple-negative breast cancer.ImmunoHorizons · 2026Article
- Visualized self-propelled nanorobots overcome tumor barriers for boosted photothermal-nanocatalytic synergistic therapy against triple-negative breast cancer.Journal of nanobiotechnology · 2026Article
- The spatial architecture of tumor immunity: Emerging predictive biomarkers across cancer.Immunologic research · 2026Review
- Cancer-Intrinsic Protein Neddylation Modulates the Intratumoral Immune Landscape to Constrain Immune Checkpoint Blockade Therapy.Cancer immunology research · 2026Article
- Spatial and Temporal Heterogeneity of Macrophage Efferocytosis in Tumors: Emerging Implications for Immunotherapy Biomarkers and Therapeutic Timing.Cancer medicine · 2026Review
- Article
- Multimodal FRACTAL-MSI and Image Fusion Improves Detection and Resolution of Biomolecule Imaging.ACS central science · 2026Article
174 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 18 institutions in 9 countries.
Xiao Qian WangCRUK Cambridge Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0001-5269-1219
Esther DanenbergCRUK Cambridge Institute, University of Cambridge, Cambridge, UK.
Chiun-Sheng HuangNational Taiwan University Hospital, College of Medicine, National Taiwan University and Taiwan Breast Cancer Consortium, Taipei, Taiwan.
Daniel EgleDepartment of Gynecology, Brust Gesundheit Zentrum Tirol, Medical University Innsbruck, Innsbruck, Austria.ORCID 0000-0003-0283-8176
Maurizio CallariFondazione Michelangelo, Milan, Italy.
Begoña BermejoMedical Oncology, Hospital Clínico Universitario de Valencia, Biomedical Research Institute INCLIVA, Valencia, Spain.
Matteo DugoSan Raffaele Hospital, Milan, Italy.
Claudio ZamagniIRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, Italy.
Marc ThillDepartment of Gynecology and Gynecological Oncology, Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany.ORCID 0000-0002-8800-8044
Anton AntonHospital Universitario Miguel Servet, Zaragoza, Spain.
Stefania ZambelliSan Raffaele Hospital, Milan, Italy.
Stefania RussoDepartment of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
Eva Maria CiruelosHospital Universitario 12 de Octubre, Madrid, Spain.
Richard Greil3rd Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria.
Balázs GyőrffyDepartment of Bioinformatics, Semmelweis University, Budapest, Hungary.
Vladimir SemiglazovNN Petrov Research Institute of Oncology, St. Petersburg, Russia.
Marco ColleoniIEO, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
Catherine M KellyMater Private Hospital, Dublin and Cancer Trials Ireland Breast Group, Dublin, Ireland.
Gabriella MarianiFondazione IRCSS - Istituto Nazionale Tumori, Milan, Italy.
Lucia Del MastroIRCCS Ospedale Policlinico San Martino, UO Clinica di Oncologia Medica, Genoa, Italy.ORCID 0000-0002-9546-5841
Olivia BiasiIEO, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
Robert S SeitzOncocyte Corporation, Irvine, CA, USA.ORCID 0000-0002-5806-2840
Pinuccia ValagussaFondazione Michelangelo, Milan, Italy.ORCID 0000-0003-3590-7916
Giuseppe VialeIEO, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
Luca GianniFondazione Michelangelo, Milan, Italy.
Giampaolo BianchiniFondazione Michelangelo, Milan, Italy. bianchini.giampaolo@hsr.it.ORCID 0000-0002-6790-6267
H Raza AliCRUK Cambridge Institute, University of Cambridge, Cambridge, UK. raza.ali@cruk.cam.ac.uk.ORCID 0000-0001-7587-0906
Fondazione Michelangelo · ITUniversity of Cambridge · GBIstituti di Ricovero e Cura a Carattere Scientifico · ITAgaplesion Markus Hospital · DEAzienda USL di Bologna · ITBrustGesundheitZentrum Tirol · ATCancer Trials Ireland · IEFondazione IRCCS Istituto Nazionale dei Tumori · ITHospital Universitario 12 De Octubre · ESHospital Universitario Miguel Servet · ESInstitute of Oncology NN Petrov · RUNational Taiwan University Hospital · TWOspedale Policlinico San Martino · ITParacelsus Medical University · ATSemmelweis University · HUUniversitat de València · ESUniversity of Milan · ITVita-Salute San Raffaele University · IT
Funding
Cancer Research UK 25815
Abstract
Immune checkpoint blockade (ICB) benefits some patients with triple-negative breast cancer, but what distinguishes responders from non-responders is unclear
Indexed as
ImmunotherapyT-LymphocytesTriple Negative Breast NeoplasmsBiopsyB-LymphocytesCD8-Positive T-LymphocytesGranzymesHepatocyte Nuclear Factor 1-alphaHistocompatibility Antigens Class IIHumansLewis X AntigenNeoadjuvant TherapyPrecision MedicinePrognosisRandomized Controlled Trials as TopicGranzymesHepatocyte Nuclear Factor 1-alphaHistocompatibility Antigens Class IIHNF1A protein, humanLewis X Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT06518382ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.